Core Viewpoint - Rosen Law Firm is reminding investors who purchased Zynex, Inc. securities between March 13, 2023, and March 11, 2025, of the May 19, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Zynex securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the Court by May 19, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that Zynex failed to disclose that it shipped products in excess of need, which inflated its revenue [4] - It is claimed that Zynex's practice of filing false claims attracted scrutiny from insurers, including Tricare, leading to potential adverse consequences [4] - The lawsuit asserts that the defendants' positive statements about Zynex's business were materially misleading and lacked a reasonable basis, resulting in investor damages when the truth was revealed [4]

Zynex (ZYXI) Q1 2025 Earnings Call April 29, 2025 04:15 PM ET Company Participants Brian Prenoveau - Investor RelationsThomas Sandgaard - Chairman, President and CEOAnna Lucsok - Chief Operating OfficerDonald Gregg - President of Zynex Monitoring SolutionsDan Moorhead - Chief Financial OfficerYi Chen - Managing Director, Equity Research Conference Call Participants Shagun Singh - Medical Technology Analyst Operator Afternoon, ladies and gentlemen, and welcome to the Zynex First Quarter twenty twenty five Ea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc. (Exact name of registrant as specified in its charter) | NEVADA | 90-0275169 | | --- | --- ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Exhibit 99.1 Zynex Reports First Quarter 2025 Financial Results ENGLEWOOD, Colo., April 29, 2025 -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary "In the first quarter of 2025, we continued to see steady orders for our pain management a ...

Core Insights - Zynex, Inc. reported a net revenue of $26.6 million for Q1 2025, a decrease from $46.5 million in Q1 2024, primarily due to a temporary suspension of payments from its largest insurance customer, Tricare [4][6] - The company experienced a net loss of $10.4 million, or $0.33 per share, compared to a net income of $10,000 in the same quarter last year [6][18] - Zynex plans to submit its FDA application for the NiCO laser pulse oximeter soon, which is expected to drive new customer acquisition and diversify its product offerings [3] Management Commentary - The company noted a 3% year-over-year decrease in total orders, attributed to a 39% reduction in sales force headcount, but expressed optimism about the productivity of the remaining sales representatives [2] - Zynex is appealing the payment suspension from Tricare and expects a response by June 2025 [2] Financial Performance - Gross profit for Q1 2025 was $18.2 million, representing 69% of revenue, down from 80% in Q1 2024, impacted by the Tricare payment suspension [4] - Sales and marketing expenses decreased by 28% to $16.9 million, while general and administrative expenses rose to $14.4 million from $13.3 million year-over-year [5] Cash Flow and Guidance - Cash flows from operations for Q1 2025 were negative at $10.5 million, with cash and cash equivalents at $23.9 million as of March 31, 2025 [7] - The company anticipates Q2 2025 net revenue of at least $27 million and expects to improve loss per share to ($0.20) or better [8] Balance Sheet Highlights - As of March 31, 2025, Zynex had total assets of $105.8 million, down from $122.1 million at the end of 2024 [15][17] - Current liabilities were $16.3 million, with total liabilities amounting to $85 million [16][17]

Core Viewpoint - A class action securities lawsuit has been filed against Zynex, Inc. for alleged securities fraud affecting investors between March 13, 2023, and March 11, 2025 [1] Group 1: Allegations - The lawsuit claims that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [2] - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including the U.S. military health insurance program, Tricare [2] - The lawsuit suggests that Zynex may face adverse consequences such as removal from insurer networks and penalties from the federal government [2] - Defendants' positive statements regarding Zynex's business, operations, and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Next Steps for Investors - Investors who suffered losses in Zynex, Inc. during the relevant time frame have until May 19, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4]

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI). Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form/?id=145088&from=3 CLASS PERIOD: March 13, 2023 to Marc ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Zynex, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from March 13, 2023, to March 11, 2025 [1] Group 1: Allegations Against Zynex, Inc. - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [1] - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [1] - As a result of these practices, Zynex is likely to face adverse consequences, including removal from insurer networks and penalties from the federal government [1] - The positive statements made by the defendants about the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1] Group 2: Class Action Details - Shareholders who purchased shares of ZYXI during the specified class period are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment [1] - The deadline for shareholders to register for the class action is May 19, 2025, and there is no cost or obligation to participate [2] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [2] Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3] - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3] - The firm seeks recovery for investors who incurred losses due to false or misleading statements that led to artificial inflation of the company's stock [3]

PHILADELPHIA, April 24, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Zynex securities during the Class Period may, no later than MAY 19, 2025, seek to be appointed as a lead plaintiff representative of the ...